Key facts
- LaCAR MDx Technologies’s last known valuation is $24.8M (Apr 2026).
- It has raised $20.3M; the latest was Later Stage VC ($7.1M) in Apr 2026.
- Notable investors include Noshaq, Venture Lab.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for LaCAR MDx Technologies
- ·The full record, as it builds
Funding rounds
No funding rounds for LaCAR MDx Technologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LaCAR MDx Technologies
Developer of isothermal amplification kits intended to detect single nucleotide polymorphisms. The company's kits provide a diagnosis based simply on DNA analysis immediately and in a way that is easy to perform and interpret and therefore cheaper than existing methods, enabling medical physicians to have access to original and innovative techniques of molecular genetic diagnosis.
- Sector
- Healthcare
- HQ
- Liege, Belgium
- Founded
- 2013
- Employees
- 78
- Website
- lacar-mdx.com/
- Ownership
- Privately Held (backing)
LaCAR MDx Technologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LaCAR MDx Technologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LaCAR MDx Technologies in its N-PORT filings yet. We sweep new filings monthly.